Meconiuom from newborns is typically used to screen for drug use by the mother during pregnancy. Drugs accumulate in meconium by fetal excretion into bile and amniotic fluid. Meconium is typically screened for various drug categories via immunoassay. To increase sample throughput while reducing the amount of meconium necessary for testing, a Laser Diode Thermal Desorption Mass Spectrometry (LDTD®-MS/MS) method was developed for analyzing 26 drugs of abuse in meconium. The LDTD® ion source uses a laser diode to vaporize dry samples from a 96-well plate, after which the sample is carried by a gas into a corona discharge region, resulting in high efficiency protonation and strong resistance to ionic suppression. The use of the LDTD® ion source enables samples to be processed at a run time of only 9 seconds.
The goal of obtaining no false negative results was achieved with this new LDTD-MS/MS method. By combining the efficient and complete hydrolysis capability of IMCSzyme® with the ultrafast quantification ability of the LDTD-MS/MS system, meconium patient samples were able to be prepared and screened for 26 different drug analytes in a matter of minutes.
Summary by IMCS from the technical poster “Meconium Targeted Drug Screening in 9 seconds per Sample Using Laser Diode Thermal Desorption Mass Spectrometry (LDTD-MS/MS)” presented by Serge Auger – Phytronix at ASMS 2016